Beck Bode LLC Has $2.63 Million Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Beck Bode LLC reduced its stake in shares of HealthEquity, Inc. (NASDAQ:HQY) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 39,598 shares of the company’s stock after selling 1,864 shares during the quarter. Beck Bode LLC’s holdings in HealthEquity were worth $2,625,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. FMR LLC increased its stake in shares of HealthEquity by 19.1% in the third quarter. FMR LLC now owns 5,648,992 shares of the company’s stock valued at $412,659,000 after buying an additional 907,743 shares during the period. Clearbridge Investments LLC raised its holdings in shares of HealthEquity by 12.1% in the 3rd quarter. Clearbridge Investments LLC now owns 2,204,675 shares of the company’s stock worth $161,051,000 after acquiring an additional 238,116 shares during the last quarter. Mackenzie Financial Corp grew its stake in shares of HealthEquity by 58.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company’s stock worth $119,831,000 after acquiring an additional 664,979 shares in the last quarter. Van Berkom & Associates Inc. boosted its holdings in shares of HealthEquity by 5.2% in the 3rd quarter. Van Berkom & Associates Inc. now owns 1,042,470 shares of the company’s stock worth $76,152,000 after buying an additional 51,824 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in HealthEquity by 2.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 980,517 shares of the company’s stock valued at $71,627,000 after acquiring an additional 26,868 shares during the period. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Activity

In related news, EVP Delano Ladd sold 2,558 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $82.59, for a total value of $211,265.22. Following the sale, the executive vice president now directly owns 47,438 shares in the company, valued at $3,917,904.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other HealthEquity news, EVP Delano Ladd sold 2,558 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $82.59, for a total transaction of $211,265.22. Following the sale, the executive vice president now directly owns 47,438 shares of the company’s stock, valued at $3,917,904.42. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares of the company’s stock, valued at $10,106,739.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,322 shares of company stock valued at $5,682,895. 2.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HQY shares. Barclays boosted their price objective on shares of HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Bank of America boosted their price target on shares of HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Royal Bank of Canada upped their target price on HealthEquity from $90.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, March 20th. KeyCorp boosted their price target on shares of HealthEquity from $85.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Finally, BTIG Research upped their price target on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, HealthEquity currently has an average rating of “Moderate Buy” and an average target price of $96.17.

HealthEquity Stock Performance

Shares of NASDAQ HQY traded down $1.39 during trading hours on Tuesday, hitting $78.91. 481,175 shares of the company’s stock were exchanged, compared to its average volume of 593,529. HealthEquity, Inc. has a 1-year low of $48.86 and a 1-year high of $84.49. The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of 125.47, a PEG ratio of 1.31 and a beta of 0.53. The company’s 50-day moving average price is $80.99 and its 200-day moving average price is $74.53. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.76 and a quick ratio of 4.76.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.08. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. The firm had revenue of $262.39 million during the quarter, compared to analyst estimates of $258.56 million. On average, sell-side analysts expect that HealthEquity, Inc. will post 2.12 earnings per share for the current fiscal year.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.